GlobeNewswire by notified

Biognosys Presents Technological Innovations and Scientific Progress to Make the Proteome Actionable for Life Science Research at the HUPO 2023 World Congress

  • Library-free and machine learning-augmented data analysis with Spectronaut® 18 yields industry-leading protein quantification and throughput for DIA proteomics
  • Novel collaborative research using the TrueDiscovery® and TrueTarget® CRO services platforms demonstrates the quantitative precision and wide applicability of mass spectrometry proteomics for biomarker discovery and drug development
  • Biognosys’ iRT Kit is cornerstone of Bruker’s novel real-time performance monitoring within ProteoScape™ analytics for timsTOF instruments

ZUERICH, Switzerland and CAMBRIDGE, Massachusetts, Sept. 15, 2023 (GLOBE NEWSWIRE) -- Biognosys, a leading inventor and developer of mass spectrometry (MS)-based proteomics solutions, announced today their attendance at the Human Proteome Organization (HUPO) World Congress from September 17 to September 21 in Busan, South Korea.

During the Technological Advancements session on Tuesday, September 19, Biognosys’ Chief Technology Officer Dr. Lukas Reiter will give a Keynote presentation “Bottom-up Proteomics using DIA” on the evolution, recent developments, and future of data-independent acquisition (DIA) in MS-based proteomics. Biognosys also will present ten posters showcasing technological innovations and novel scientific data with its proprietary proteomics research services, software, and kits. Biognosys’ team of scientific experts will be exhibiting and offering software demos at booth #408.

Biognosys’ strategic partner Bruker will introduce novel concepts for the timsTOF platform and Bruker ProteoScape™ software suite, forging synergies with Biognosys’ Spectronaut® software and iRT Kit to offer customers enhanced capabilities for high-fidelity, high-throughput proteomics.

“I am thrilled to present significant advances with Biognosys’ MS proteomics technology and solutions that bring us again closer to making the proteome truly actionable for research, drug development, and clinical decision-making,” commentedDr.Lukas Reiter. “Our continuously improving software and well-established kits empower users of major MS instruments to perform cutting-edge, hassle-free workflows for deep, high-throughput, reproducible proteomics research in-house. Our CRO services provide biopharma and diagnostics customers with unparalleled precision and insights to expedite biomarker discovery and drug development.”

Spectronaut® 18: Industry-leading depth, throughput, and efficiency for DIA data analysis

Spectronaut 18, the latest version of Biognosys’ flagship software, offers a significantly further improved identification rate and quantification quality, as well as various new features that make DIA proteomics more efficient and scalable. At HUPO, Biognosys will present three posters highlighting powerful applications of Spectronaut 18 for comprehensive proteome quantification. Remarkable innovations include the utilization of directDIA+™ for faster, library-free analysis, and deep learning with DeepQuant to enhance the quantification of low-abundant proteins through a neural network for interference correction of precursor quantities.

TrueDiscovery®: Proven precision forbiomarker discovery in oncology and neuroscience

Biognosys will present three posters showcasing biomarker discovery and drug development research conducted with esteemed collaborators, including Genmab, Johns Hopkins University School of Medicine, Stanford University, and University of Zuerich. The studies utilized Biognosys’ TrueDiscovery platform for unbiased proteomics and collectively demonstrate the quantitative precision, robustness, and wide applicability of MS proteomics for oncology and neuroscience research. A fourth poster evaluates the technological and biological complementarity of TrueDiscovery and the Olink® Explore affinity-based platform of Olink Proteomics AB for plasma proteomics.

TrueTarget®: Efficient target deconvolution and binding sites mapping in drug discovery

Biognosys’ TrueTarget platform leverages limited proteolysis mass spectrometry (LiP-MS) to facilitate drug target identification and validation. A first poster, in collaboration with InterAx, demonstrates TrueTarget’s unique capabilities in deconvoluting the target of a G-Protein Coupled Receptor (GPCR) antagonist, mapping its binding sites, and providing structural insights on the mechanism of action. A second poster, in collaboration with Samsara Therapeutics, illustrates how target deconvolution with TrueTarget, followed by unbiased proteome profiling with TrueDiscovery, enabled the efficient identification and validation of target proteins and enhanced understanding of biological systems in novel therapeutic development.

Biognosys and Bruker: Seamless workflows for dia-PASEF® and QC on timsTOF

To ensure optimal MS performance, Bruker introduces TwinScape™, a digital twin for the timsTOF platform, interlinked with ProteoScape software to support real-time quality control (QC) with the Biognosys iRT Kit. The peptides in the iRT Kit have been carefully optimized for stability, sensitivity and retention time spacing, and this iRT Kit can now be used for system QC in Bruker’s proteomics software ProteoScape. Biognosys’ Head of Business Development – Products, Dr. Sira Echevarria, will present how Spectronaut offers improved library-free proteomics analysis for dia-PASEF using directDIA+ during Bruker’s HUPO lunch seminar on Tuesday, September 19.

Visit for a complete overview of Biognosys’ presence at HUPO. Posters will be available for download from Friday, September 22.

About Spectronaut®

Spectronaut is Biognosys’ flagship data analysis software for data-independent acquisition (DIA) mass spectrometry (MS) based proteomics.

The software employs advanced Search and Artificial Intelligence (AI) algorithms to translate data into actionable insights for life science research. Spectronaut enables reproducible and precise quantification of thousands of proteins in a single experiment and provides multi-dimensional insights into protein expression, function, and structure across all major biological species and sample types. For more information, visit

About TrueDiscovery®

The Biognosys TrueDiscovery platform offers integrated proteomics solutions across the entire drug development pipeline.

TrueDiscovery is powered by Hyper Reaction Monitoring (HRM) mass spectrometry, an advanced Data Independent Acquisition (DIA)-based protein quantification technology co-invented and patented by Biognosys.

TrueDiscovery is the only platform that searches the complete proteome to quantify thousands of the most relevant proteins, including an unlimited number of proteoforms. The platform enables the deepest unbiased profiling of tissue and biofluids proteomes with unbeatable specificity on a large scale. The generated data are highly reproducible and easily transferrable to clinical assays. Studies can be performed in a GLP certified and GCP compliant environment. For more information, visit

About TrueTarget®

The Biognosys TrueTarget proteomics platform uniquely addresses the most pressing challenges in early drug discovery by identifying on- and off-targets to accelerate and de-risk drug development throughout the pipeline.

TrueTarget is powered by Limited Proteolysis Mass Spectrometry (LiP-MS), a proprietary, patented chemoproteomics technology co-developed by Biognosys. TrueTarget is the only tool to probe structural changes across the complete proteome with peptide-level resolution, providing unique insights into compound binding and target identification.

The platform enables elucidating mechanisms of action and revealing unanticipated toxicities. For more information, visit

About Biognosys

At Biognosys, we believe that deep proteome insights hold the key to breakthrough discoveries that transform science for better lives. With our versatile portfolio of next-generation proteomics solutions, including the TrueDiscovery®, TrueTarget®, and TrueSignature® research service platforms, our flagship software Spectronaut®, and the PQ500™ kit, we make the proteome actionable to empower research, drug development, and clinical decision-making. Our solutions provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Our unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins with industry-leading precision, depth, and throughput. Through our strategic partnership with Bruker (Nasdaq: BRKR), we make proteomics globally accessible. For more information, visit

To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 20234.12.2023 22:30:00 CET | Press release

Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2023 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights11/30/2023 96,431,770 Total gross of voting rights: 96,431,770 Total net* of voting rights: 96,186,256 * Net total = total number of voting rights attached to shares – shares without voting rights Attachment PDF Version

Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc.4.12.2023 22:16:59 CET | Press release

Aggregate gross proceeds of approximately €50.9 million (equivalent to approximately $53.8 million) received by NANOBIOTIX has increased to approximately €55.5 million (equivalent to approximately $58.7 million) extending its runway into mid’ 2025 PARIS and CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announces today the closing of the previously announced subscription by Johnson & Johnson Innovation – JJDC, Inc. (“JJDC”) for 901,256 additional ordinary shares of the Company, in the form of restricted American Depositary Shares (“ADSs”), for an aggregate amount of $4.8 million, equivalent to €4.6 million1 (the “Remaining Placement Amount”, and the subscription transaction being the “Remaining Placement”), following the approval by the French Ministry of Economy of JJ

Inventiva announces the positive recommendation of the third DMC of the Phase III clinical trial with lanifibranor in patients with NASH4.12.2023 22:05:00 CET | Press release

The DMC recommended to continue the clinical trial without modification of the protocol, based on the pre-planned review of safety dataThe safety assessment was based on the review of safety data from more than 500 patients, including patients that have been treated with lanifibranor for more than 72 weeksThe DMC review remains consistent, confirming the good safety profile of lanifibranor Daix (France), Long Island City (New York, United States), December 4, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced the positive recommendation from the third meeting of the Data Monitoring Committee (DMC) to continue the NATiV3 Phase III clinical trial evaluating lanifibranor in patients with NASH without modification to the trial protocol. The DMC

Standard Lithium to Participate in December Investor Conferences4.12.2023 22:04:35 CET | Press release

VANCOUVER, British Columbia, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV:SLI) (NYSE American:SLI) (FRA:S5L), a leading near-commercial lithium development company, today announced its participation in the following virtual December investor conferences: Event:Deustche Bank 8th Annual Virtual Lithium Battery Supply Chain ConferenceDate:December 6, 2023Panel:US Based Lithium Supply, featuring Robert Mintak, CEO and Director of Standard Lithium, 7:45am – 8:15am PTEvent:Bank of America Securities Virtual 2023 Lithium and Battery Storage ConferenceDate:December 7, 2023Panel:Company Presentation, featuring Robert Mintak, CEO and Director of Standard Lithium, 7:45am – 8:30am PT Management will be hosting one-on-one meetings during the conferences. Interested investors should contact their Deutsche Bank or Bank of America representative or Standard Lithium Investor Relations at About Standard Lithium Ltd. St

Resignation of Director4.12.2023 20:00:33 CET | Press release

December 4, 2023 Announcement no. 19 Resignation of Director COPENHAGEN, DENMARK and BOSTON, MA, USA, December 4, 2023, (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) announced today that Jan Leth Christensen has informed the Company that he has decided to resign from his position as a board member for BioPorto. The search for a successor with relevant expertise, including familiarity with public company practices in the Nordics, will be initiated and a new candidate is expected to be proposed in connection with the Company’s Annual General Meeting in 2024. “Jan has served on the board since the Annual General Meeting held in 2021. I would like to thank Jan for his important contributions to the board and collaboration in general” said John McDonough, BioPorto’s Chaiman of the Board of Directors. For investor inquiries, please contact: HC Andersen Capital, EU Investor Relations, +45 4529 0000, Ashley R. Robinson, US Investor Relations,